Phase 1B study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated advanced cancers and metastatic colorectal cancer.

Authors

David S. Hong

Department of Investigational Cancer Therapeutics (Phase I Program), University of Texas MD Anderson Cancer Center, Houston, TX

David S. Hong , Van Karlyle Morris II, Siqing Fu , Michael J. Overman , Sarina Anne Piha-Paul , Bryan K. Kee , Ralph Zinner , David R. Fogelman , Reena Mistry , Imad Shureiqi , Funda Meric-Bernstam , Scott Kopetz

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Highlights Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer

Clinical Trial Registration Number

NCT01787500

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 3516)

DOI

10.1200/jco.2014.32.15_suppl.3516

Abstract #

3516

Poster Bd #

Abstract Disclosures

FEATURED

Phase 1B study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated advanced cancers and metastatic colorectal cancer.

Authors

David S. Hong

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.